Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

0 / 5 (0 votos)

American Journal of Hematology

Fecha de publicación: 5 october 2018

DOI: https://doi.org/10.1002/ajh.25306

Autores: Rüdiger Hehlmann, Jorge E. Cortes, Teresa Zyczynski, Carlo Gambacorti‐Passerini, Stuart L. Goldberg, Michael J. Mauro, Mauricette Michallet, Bengt Simonsson, Loretta A. Williams, et al.  

Background: SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor (TKI) use and management patterns in patients with chronic phase‐chronic myeloid leukemia in the US and Europe in routine clinical practice. 

Seguir leyendo